Detection of specific genes related to drug action can provide scientific guidance for personalized medicine. Taking the detection of a single-nucleotide polymorphism (SNP) genotyping related to the chronic hepatitis B virus (HBV) therapy as an example, a novel biosensor with high sensitivity and selectivity was developed based on the hyperbranched rolling circle amplification (HRCA) in this work. The single-base mutant DNA (mutDNA) sequence can perfectly hybridize with the specially designed discrimination padlock probe and initiate the HRCA reaction. Subsequently, a great abundant of double-strand DNA sequences were released and a strong fluorescence signal can be detected after adding SYBR Green I. In particular, the enhanced fluorescence intensity exhibits a linear relationship with the logarithm of mutDNA concentration ranging from 0.1 nM to 40 nM with a low detection limit of 0.05 nM. However, when there was even a single base mismatch in the target DNA, the HRCA was suppressed and fluorescence response process could not occur, resulting in a high selectivity of this biosensor. Moreover, this detection strategy also performs well in human serums, demonstrating its potential application in detecting SNPs in real biological samples.

与药物作用有关的特定基因的检测可以为个性化药物提供科学指导。以与慢性乙型肝炎病毒（HBV）治疗相关的单核苷酸多态性（SNP）基因型检测为例，在此基础上，基于超支化滚环扩增（HRCA），开发了一种具有高灵敏度和选择性的新型生物传感器。工作。单碱基突变DNA（mutDNA）序列可以与专门设计的鉴别挂锁探针完美杂交，并启动HRCA反应。随后，加入SYBR Green I后释放出大量双链DNA序列，并且可以检测到强荧光信号。特别是增强的荧光强度与mutDNA浓度从0的对数呈线性关系。1 nM至40 nM，检测下限为0.05 nM。但是，当目标DNA中甚至只有一个碱基错配时，HRCA受到抑制，并且荧光反应过程不会发生，从而导致该生物传感器的高选择性。此外，这种检测策略在人血清中也表现良好，证明了其在检测真实生物样品中SNP方面的潜在应用。